Richter Gedeon Vegyeszeti Gyar Rt

Gabor Megyeri

Tibor Keve

Laszlo Szporny

Bela Stefko

Ferenc Trischler

Erik Bogsch

Eva Palosi

Bela Kiss

Erzsebet Lapis

Istvan Laszlovszky

Janos Galambos

Dora Groo

Lajos Kovacs

Egon Karpati

Csaba Szantay

Gyorgy Hajos

Elemer Ezer

Gyorgy Fekete

Zsolt Szombathelyi

Hedvig Bolcskei

Maria Gazdag

Tibor Acs

Gabor Szepesi

Tibor Cs

Anna Kassai Nee Zieger

Anna Kassainee Zieger

Bala Stefko

Anna Kassi Nee Zieger

Anna Kassia Nee Zieger

The invention relates to novel 2-halogenated 8- and 1,8-substituted ergolene derivatives of the formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## wherein X stands for a halogen;

2-Halogenated-8- and 1,8-substituted ergolenes

The invention relates to a novel process for the halogenation in 2-position of ergot alkaloids. The process is characterized by that as a halogenating agent a system consisting of dimethylsulfoxide, a trialkylhalosilane or triarylhalosilane and optionally a hydrogen halide is used.

Process for the preparation of 2-halogenated ergoline derivatives

The invention relates to a novel process for the preparation of partially new 2-halonicergoline derivatives of the formula (I), ##STR1## wherein X stands for chlorine, bromine or iodine atom, as well as their acid addition salts. The process of the invention comprises esterifying a novel 2-halo-1-methyllumilysergol of the formula (II), ##STR2## wherein X is the same as defined above, or an acid addition salt thereof and, if desired, converting the thus-obtained 2-halonicergoline derivative of the formula (I) to an acid addition salt. The compounds of the invention improve the cognitive function of the brain and show an antihypoxic as well as a strong .alpha.-adrenerg blocking and calcium-antagonistic action.

2-chloronicergoline having antihypoxic activity

The invention relates to a novel process for the preparation of 2-bromo-.alpha.-ergocryptine and its acid addition salt by brominating .alpha.-ergocryptine in such a way that the bromination is carried out at room temperature by using a dimethylsulphoxide-hydrogen bromide mixture containing no more 0.02% of water and, if desired, converting the thus-obtained 2-bromo-.alpha.-ergocryptine to an acid addition salt in a known manner.

Process for the preparation of 2-bromo-.alpha.-ergocryptine

The invention relates to pharmaceutical compositions with a neuroleptic action as well as to a process for preparing these compositions. The active ingredients of the compositions of the invention are 2-halo-6-methyl-9-ergolene derivatives of the formula (I), ##STR1## wherein X represents a chlorine, bromine or iodine atom as well as their acid addition salts. The compositions of the invention contain an effective dose of compound of the general formula (I) or an acid addition salt thereof.

Pharmaceutical compositions with a neuroleptic action and process for

The invention relates to new indolo[2,3-g]cyclopent[a]indolizine derivatives of the formulae (II) ##STR1## and/or (III) ##STR2## wherein W is alkoxycarbonyl having from one to four carbon atoms in the alkoxy moiety or cyano,

Indolo[2,3-a]quinolizine and indolo[2,3-g]cyclopent[a]indolizine

The invention relates to new 2-azabicyclo[2.2.2]octane derivatives of the formula (I), ##STR1## wherein A is hydrogen, alkoxycarbonyl having from one to 4 carbon atoms in the alkoxy group, phenylalkoxycarbonyl having from one to 4 carbon atoms in the alkoxy moiety, alkyl having from one to 6 carbon atoms, aralkyl containing from one to 4 carbon atoms in the alkyl moiety or substituted acyl,

2-Azabicyclo(2.2.2)octane derivatives and their use as immunosuppressive

Growing community of inventors

Budapest, Hungary

Gabor Megyeri